At the last check on Friday, ARS Pharmaceuticals Inc.’s (NASDAQ:SPRY) stock was up $0.54, moving up 7.62 percent to $7.63. The average number of shares traded per day over the past five days has been 455,366 shares. 4 times new highs have been achieved over the past 5 days, with a $0.86 gain in that time frame. In the last twenty days, the average volume was 358,156, while in the previous 50 days, it was 473,689.
Since last month, SPRY stock rose 9.00%. Shares of the company fell to $6.48 on 08/17/23, the lowest level in the past month. A 52-week high of $9.65 was reached on 05/12/23 after having rallying from a 52-week low of $3.99. Since the beginning of this year, SPRY’s stock price has dropped by -10.55% or -$0.73, and marked a new high 3 times. However, the stock has declined by -20.93% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
SPRY stock investors should be aware that ARS Pharmaceuticals Inc. (SPRY) stock had its last reported insider trading activity 3 days ago on Aug 29. RA CAPITAL MANAGEMENT, L.P., the Director of the company, purchased of 3,750,000 shares for $6.20 on Aug 29. It resulted in a $23,250,000 investment by the insider. ORBIMED ADVISORS LLC added 500,000 shares at an average price of $6.20 on Aug 29. The insider now owns 8,019,187 shares following the transaction. On Aug 29, Director Thompson Peter A. bought 500,000 shares at $6.20 apiece. The transaction was valued at $3,100,000.
Valuation Metrics
The stock’s beta is -0.12. Besides these, the trailing price-to-sales (P/S) ratio of 557.64, the price-to-book (PB) ratio of 2.91.
Financial Health
In the three months ended June 29, ARS Pharmaceuticals Inc.’s quick ratio stood at 25.40, while its current ratio was 25.40, showing that the company is able to pay off its debt. Based on annual data, SPRY earned $36.83 million in gross profit and brought in $1.32 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -13.00%. Return on equity (ROE) for the past 12 months was -8.70%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. SPRY’s revenue rose 100.0% during the quarter, while net income inched up to $10000.0. While analysts expected ARS Pharmaceuticals Inc. to report -$0.17 quarterly earnings, the actual figure was -$0.18 per share, beating the consensus estimate by -5.90%. During the quarter, the company generated -$22.34 million in EBITDA. The liabilities of ARS Pharmaceuticals Inc. were 10.2 million at the end of its most recent quarter ended June 29, and its total debt was $0.38 million. The value of shareholders’ equity is $95.57 million.
Technical Picture
This quick technical analysis looks at ARS Pharmaceuticals Inc.’s (SPRY) price momentum. With a historical volatility rate of 47.54%, the RSI 9-day stood at 79.77% on 31 August.
With respect to its five-day moving average, the current ARS Pharmaceuticals Inc. price is up by +12.39% percent or $0.86. At present, SPRY shares trade +10.95% above its 20-day simple moving average and +32.65% percent above its 100-day simple moving average. However, the stock is currently trading approximately +21.50% above its SMA50 and +26.62% above its SMA200.
Stochastic coefficient K was 67.94% and Stochastic coefficient D was 60.17%, while ATR was 0.33. Given the Stochastic reading of 86.84% for the 14-day period, the RSI (14) reading has been calculated as 70.84%. As of today, the MACD Oscillator reading stands at 0.23, while the 14-day reading stands at 0.32.
Analyst Ratings
Wedbush launched its rating on ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to an Outperform in a note to investors on January 31, 2023. ARS Pharmaceuticals Inc. (SPRY) has been rated Buy by analysts. According to 0 brokerage firms, SPRY is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate ARS Pharmaceuticals Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $14.00, the current consensus forecast for the stock is $13.00 – $15.00. Based on these forecasts, analysts predict ARS Pharmaceuticals Inc. (SPRY) will achieve an average price target of $14.00.
